Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02418507
Other study ID # 14PPHU
Secondary ID
Status Completed
Phase Phase 2
First received March 6, 2015
Last updated December 12, 2017
Start date May 29, 2015
Est. completion date May 2016

Study information

Verified date December 2017
Source KGK Synergize Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective for this study is to monitor the change in patient assessed symptoms of constipation in subjects taking the proprietary probiotic blend compared to those taking the placebo. The secondary objective for this study is to additionally monitor changes in stool consistency, stool frequency, quality of life and microbial composition of feces from baseline to Day 29, in all subjects. Safety considerations monitored any changes in blood safety parameters as well as incidence of adverse events throughout the entire study for all subjects.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date May 2016
Est. primary completion date April 1, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Healthy male or female adults, aged 18 to 65 years

- BMI of 18.5 kg/m2 to 35.0 kg/m2 (inclusive)

- Subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:

- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)

- Double-barrier method (condoms with spermicide or diaphragm with spermicide)

- Non-hormonal intrauterine devices

- Vasectomy of partner

- Non-heterosexual lifestyle

- Subjects must have at least two of the following criteria based on subject self-reporting, for the past 3 months with the symptoms beginning at least 6 months ago:

- Two or more criteria must be met by subjects:

1. Straining during at least 25% of defecations

2. Lumpy or hard stools in at least 25% of defecations

3. Sensation of incomplete evacuation for at least 25% of defecations

4. Sensation of anorectal obstruction/blockage for at least 25% of defecations

- Fewer than three defecations per week

- Loose stools are rarely present without the use of laxatives

- Insufficient criteria for Irritable Bowel Syndrome

- Subjects with an average stool type of < 3 on the Bristol Stool Scale as assessed over the two week run-in period (confirmed at baseline review of bowel habits diary).

- Subjects who agree to maintain their current level of physical activity throughout the trial period.

- Subjects who agree to discontinue the use of probiotic supplements including foods supplemented with probiotics (i.e. yogurts) or fiber supplements including foods labeled as supplemented with fiber

- Subjects who agree to discontinue use of over-the-counter laxative medications (other than the rescue medication provided) within 2 weeks of screening and throughout the trial.

- Subjects who successfully complete the run-in period by completing at least 80% of Run-In diary entries, 100% of IPAQ questionnaires and provide fecal sample.

- Subjects who understand the nature and purpose of the study including the potential risks and side effects

- Subjects who are willing to complete all study procedures including study related questionnaires and comply with study requirements

- Subjects who have given voluntary, written, informed consent to participate in the study.

Exclusion Criteria:

- Subjects who are pregnant, breastfeeding or planning on becoming pregnant throughout the course of the study.

- Subjects with any unstable medical conditions

- Subjects with any major diseases of the cardiovascular, renal, hepatic, gastrointestinal, pulmonary or endocrine systems

- Subjects with Type I or Type II diabetes

- Subjects with a history of major gastrointestinal complications (i.e. Crohn's disease, ulcer, cancer, ulcerative colitis)

- History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable

- Subjects with neurological disorders or significant psychiatric illnesses (significance determined by the Qualified Investigator)

- Subjects who are immuno-compromised (HIV positive, on anti-rejection medication, rheumatoid arthritis)

- Subjects with any medical condition or a history of abdominal surgery that is deemed exclusionary by the Qualified Investigator

- Subjects who have features which may suggest a more serious underlying cause of chronic constipation such as rectal bleeding, anemia, abrupt weight loss ( 5kg or more within the past month prior to randomization), gastrointestinal polyps, first degree family history of colorectal cancer.

- Subjects with an active eating disorder

- Subjects who have used an over-the-counter or prescription laxative medication within 2 weeks prior to screening.

- Subjects who have used probiotic or fiber supplements (or probiotic/fiber enriched foods) within 4 weeks prior to screening

- Subjects who have used an antibiotic within 4 weeks prior to screening

- Subjects who have used medications in the investigators opinion known to cause constipation (i.e. opiates) within 4 weeks of screening

- Subjects using Medicinal Marijuana

- Subjects who use illicit drugs or have a history of alcohol or drug abuse within the past 6 months

- Subjects who currently consume greater than 2 standard alcoholic drinks per day.

- Subjects who have participated in a clinical research trial within 30 days prior to randomization.

- Subjects with an allergy or sensitivity to the investigational product ingredient

- Subjects who are cognitively impaired and/or who are unable to give informed consent

- Subjects who have abnormal laboratory results or any other medical or psychological condition which, in the opinion of the Principle Investigator, may adversely affect the subjects' ability to complete the study or its measures or which may pose significant risk to the subject.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Proprietary Probiotic Blend
A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
Other:
Placebo
The placebo is administered to randomized healthy participants

Locations

Country Name City State
Canada KGK Synergize Inc. London Ontario

Sponsors (2)

Lead Sponsor Collaborator
KGK Synergize Inc. UAS Labs LLC

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in blood safety parameters CBC, electrolytes, creatinine, AST, ALT, GGT and bilirubin Baseline to Day 29
Primary Changes in the symptoms of constipation as measured by the PAC SYM questionnaire Baseline to Day 29
Secondary Changes in stool consistency as measured by the Bristol Stool Scale Baseline to Day 29
Secondary Changes in stool frequency Weekly mean Complete Spontaneous Bowel Movements Baseline to Day 29
Secondary Changes in quality of life questionnaire score Baseline to Day 29
Secondary Changes in microbial composition of feces Baseline to Day 29
See also
  Status Clinical Trial Phase
Completed NCT04506801 - The Effect of Probiotics on Functional Constipation in the Elderly N/A
Completed NCT04620161 - A Proof of Concept Study of Pradigastat in Patients With Functional Constipation Phase 2
Active, not recruiting NCT02361749 - Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation Phase 4
Completed NCT03054805 - The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation Phase 4
Not yet recruiting NCT01913665 - The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation N/A
Completed NCT01348152 - Effect of TU-100 in Patients With Functional Constipation Phase 2
Completed NCT01622972 - Mode of Action of Moviprep Phase 4
Completed NCT01212146 - Probiotic-enriched Artichoke in Functional Constipation N/A
Completed NCT04231162 - Effect of an 8-week Bifidobacterium Lactis HN019 Supplementation on Functional Constipation N/A
Not yet recruiting NCT03639142 - Dried Plums (Prunes) vs. Polyethylene Glycol 4000 for Treatment of Functional Constipation in Children Phase 3
Recruiting NCT04918329 - Functional Digestive Disorders Observatory
Completed NCT02592200 - Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women N/A
Completed NCT03707002 - Effect of scFOS on Increase in Stool Frequency in Constipated People N/A
Recruiting NCT06083311 - The Efficacy of a Probiotic for Functional Constipation (FC) N/A
Completed NCT04110145 - Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation Phase 2
Recruiting NCT06196073 - Visceral Osteopathy in Functional Constipation N/A
Completed NCT04026113 - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) Phase 3
Completed NCT02359396 - A Randomized, Open-label, Three-arm Study of MZRW on Tolerability, Exposure and Pharmacokinetics Phase 1
Completed NCT01847950 - Effects of scFOS on Stool Frequency in People With Functionnal Constipation N/A
Recruiting NCT01274793 - Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy Phase 1